Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-81201887 for Geographic Atrophy Secondary to AMD
2022-500746-16-00Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2023
- Modality
- Gene Therapies
- Countries
- 20
01
Overview
Phase 2, randomised, double-blind trial of JNJ-81201887 in age-related macular degeneration (AMD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change in square root GA lesion area in the study eye measured on fundus autofluorescence. Started Jul 2023; status: completed.
02
Drugs
JNJ-81201887
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2022-500746-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500746-16-00.